STROBE Statement—checklist of items that should be included in reports of observational studies

Section/item	Item No	Recommendation	Reported on Page Number/Line Number	Reported on Section/Paragraph
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	Page 2/ Line 30-40.	Abstract/ Methods.
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 2-3/ Line 30-51.	Abstract/ Paragraph 2-3.
Introduction				
Background/ rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 4-5/ Line 70-108.	Introduction/ Paragraph 1-4.
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 5/ Line 108-109.	Introduction/ Paragraph 4.
Methods				
Study design	4	Present key elements of study design early in the paper	Page 6/ Line 113; Page 6/	Methods/ Subtitles.
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 6/ Line 114-128.	Methods (Acquisition and preparation of data)/
Participants	6	(a) ***Cohort study***—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up ***Case-control study***—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls ***Cross-sectional study***—Give the eligibility criteria, and the sources and methods of selection of participants	Page 6/ Line 114-116; Page 6/ Line 125-127； Page 7/ Line 146-149; Page 8/ Line 165-167;	Methods (Acquisition and preparation of data)/ Paragraph 1; Methods (Establishment of an independent prognostic index (PI, riskScore) based
		(b) ***Cohort study***—For matched studies, give matching criteria and number of exposed and unexposed ***Case-control study***—For matched studies, give matching criteria and the number of controls per case	N/A (The paired design was not used in our study.)	N/A (The paired design was not used in our study.)
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 9-10/Line 197-202；	Methods (Verification of the prognostic ability of
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 6/ Line 114-128; Page 11/ Line 234-236.	Methods (Acquisition and preparation of data)/
Bias	9	Describe any efforts to address potential sources of bias	Page 7/ Line 146-152;	Methods (Establishment
Study size	10	Explain how the study size was arrived at	Page 7/ Line 146-152.	Methods (Establishment
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 7-8/ Line 153-160; Page 8/ Line 165-167.	Methods (Establishment of an independent

Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	Page 11/ Line 224-236.	Methods (Statistical
		(b) Describe any methods used to examine subgroups and interactions	Page 11/ Line 224-236.	Methods (Statistical
		(c) Explain how missing data were addressed	Page 7/ Line 146-152.	Methods (Establishment
		(d) ***Cohort study***—If applicable, explain how loss to follow-up was addressed ***Case-control study***—If applicable, explain how matching of cases and controls was addressed ***Cross-sectional study***—If applicable, describe analytical methods taking account of sampling strategy	N/A (The paired design was not used in our study.)	N/A (The paired design was not used in our study.)
		(e) Describe any sensitivity analyses	Page 9-10/Line 197-202;	Methods (Verification of
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 12/Line 240-243; Page 13/Line 266-269;	Results (Differentially expressed prognostic
		(b) Give reasons for non-participation at each stage	Page 13/Line 266-267.	Results (Construction a
		(c) Consider use of a flow diagram	Page 12/Line 240.	Results (Differentially
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 12/Line 243-244.	Results (Differentially expressed prognostic
		(b) Indicate number of participants with missing data for each variable of interest	Page 12/Line 243-244;	Results (Differentially
		(c) ***Cohort study***—Summarise follow-up time (eg, average and total amount)	N/A (This study is not	N/A (This study is not
Outcome data	15*	***Cohort study***—Report numbers of outcome events or summary measures over time	N/A (This study is not	N/A (This study is not
		Case-control study—Report numbers in each exposure category, or summary measures of exposure	Page 14/Line 300-302;	Results (Evaluation of the
		Cross-sectional study—Report numbers of outcome events or summary measures	N/A (This study is not	N/A (This study is not
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page 14/Line 296-297; Page 18/Line 382-384.	Results (Evaluation of the prognostic model index
		(b) Report category boundaries when continuous variables were categorized	Page 13/LIne 281.	Results (Construction a
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	Page 19/Line 401-407.	Results (Nomogram
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Page 17/Line 363;	Results/Clinical
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page 20-22/Line 424-466.	Discussion/ Paragragh 2-3.
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page23-24/Line 496-501.	Discussion/ Paragragh 6.

Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 19-20/Line 410-423; Page 22-23/Line 467-495.	Discussion/ Paragragh 1; Discussion/ Paragragh 4-5.
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 21/Line 443-445;	Discussion/ Paragragh 2;
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page 24/Line 512-513.	Funding/ Paragragh 1.

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: http://dx.doi.org/10.21037/atm-20-654
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.